Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HER3 inhibitors

Bristol-Myers Squibb (BMS) building

Opdivo gets EU lung cancer nod as kidney cancer trial is halted

Bristol-MyersSquibb's checkpoint inhibitor gains European license for lung cancer

AstraZeneca AZ

Iressa set for US market return after FDA approval

AstraZeneca'slung cancer drug wins green light for EGFR tumours

Eli Lilly HQ

Lilly closes on US approval of lung cancer drug necitumumab

Indication for NSCLC looking likely after informal panel poll

Boehringer Ingelheim headquarters

Boehringer plans new filings for Giotrif in lung cancer

Firm to file drug for squamous cell carcinoma of the lung

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

FDA gives priority review for Keytruda in lung cancer

The regulator is expected to deliver a verdict by October 2 

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

- PMLiVE

AZ pushes immuno-oncology duo into phase III

MEDI4736 and tremelimumab achieved disease control in 48% of NSCLC patients

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links